Sunitinib Accord
Authorised
This medicine is authorised for use in the European Union
sunitinib
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Sunitinib Accord is a medicine used to treat adults with the following cancers:
- gastrointestinal stromal tumour (GIST), a type of cancer of the stomach and bowel where there is uncontrolled growth of cells in the supporting tissues of these organs. Sunitinib Accord is used in patients with GISTs that cannot be removed with surgery or have spread to other parts of the body. It is used after treatment with imatinib (another cancer medicine) has failed;
- metastatic renal cell carcinoma, a type of kidney cancer, that has spread to other parts of the body;
- pancreatic neuroendocrine tumours (tumours of the hormone-producing cells in the pancreas) that have spread or cannot be removed with surgery. Sunitinib Accord is used if the disease is getting worse and the tumour cells are well-differentiated (similar to normal cells in the pancreas).
Sunitinib Accord contains the active substance sunitinib and is a ‘generic medicine’. This means that Sunitinib Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Sutent.
Sunitinib Accord can only be obtained with a prescription and treatment should be started by doctors who have experience in the use of cancer medicines.
Sunitinib Accord is available as capsules of various strengths to be taken by mouth.
For GIST and metastatic renal cell carcinoma, Sunitinib Accord is given in six-week cycles, at a dose of 50 mg once a day for four weeks, followed by a two-week ‘rest period’. The dose can be adjusted according to the patient’s response to the treatment, but should be kept within the range of 25 to 75 mg.
For pancreatic neuroendocrine tumours, Sunitinib Accord is given at a dose of 37.5 mg once a day without a rest period. This dose may also be adjusted.
For more information about using Sunitinib Accord, see the package leaflet or contact your doctor or pharmacist.
The active substance in Sunitinib Accord, sunitinib, is a protein kinase inhibitor. This means that it blocks some specific enzymes known as protein kinases. These enzymes can be found at the surface of cancer cells, where they are involved in the growth and spread of cancer cells, and in the blood vessels that supply the tumours, where they are involved in the development of new blood vessels. By blocking these enzymes, Sunitinib Accord can reduce the growth and spread of the cancer and cut off the blood supply that keeps cancer cells growing.
Studies on the benefits and risks of the active substance, sunitinib, in the authorised uses have already been carried out with the reference medicine, Sutent, and do not need to be repeated for Sunitinib Accord.
As for every medicine, the company provided studies on the quality of Sunitinib Accord. The company also carried out studies that showed that it is ‘bioequivalent’ to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.
Because Sunitinib Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
The European Medicines Agency concluded that, in accordance with EU requirements, Sunitinib Accord has been shown to have comparable quality and to be bioequivalent to Sutent. Therefore, the Agency’s view was that, as for Sutent, the benefits of Sunitinib Accord outweigh the identified risks and it can be authorised for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sunitinib Accord have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Sunitinib Accord are continuously monitored. Side effects reported with Sunitinib Accord are carefully evaluated and any necessary action taken to protect patients.
Sunitinib Accord received a marketing authorisation valid throughout the EU on 11 February 2021.
Product information
Latest procedure affecting product information:
N/0003
29/05/2024
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Sunitinib Accord
- Active substance
- sunitinib
- International non-proprietary name (INN) or common name
- sunitinib
- Therapeutic area (MeSH)
- Gastrointestinal Stromal Tumors
- Carcinoma, Renal Cell
- Neuroendocrine Tumors
- Anatomical therapeutic chemical (ATC) code
- L01EX01
Pharmacotherapeutic group
Antineoplastic agentsTherapeutic indication
Gastrointestinal stromal tumour (GIST)
Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.
Metastatic renal cell carcinoma (MRCC)
Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.
Pancreatic neuroendocrine tumours (pNET)
Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.
News on Sunitinib Accord
This page was last updated on